Dopamine D3 Receptor Ligands with Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a challenge in developing dopamine D3 receptor selective antagonists or partial agonists that are both highly selective and metabolically stable, due to the high amino acid homology between D2 and D3 receptor subtypes, which has hindered the discovery of effective compounds for treating neuropsychiatric conditions such as substance use disorders.
Innovation Solution
The development of novel dopamine D3 receptor selective antagonist/partial agonist compounds, specifically those following Formula (I), which exhibit high affinity for the D3 receptor, improved metabolic stability, and selectivity over D2 receptor family members, are introduced. These compounds are designed to be administered as pharmaceutical compositions for treating neuropsychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If high affinity for D3 receptor is pursued, then selectivity over D2 receptor is improved, but metabolic stability deteriorates
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of dopamine receptor ligands through specific substitutions at defined positions (e.g., introducing fluorine atoms at specific ring positions, modifying side chain lengths and substitutions). These structural parameter changes enable the compounds to achieve both high D3 receptor selectivity and improved metabolic stability simultaneously, resolving the contradiction between selectivity and metabolic stability.
Solution Approach 2:
The patent creates composite molecular structures by combining multiple functional groups and structural elements into a single ligand molecule. The compounds incorporate a substituted benzene ring, a piperazine or piperidine ring, and various side chains with specific functional groups (hydroxyl, alkoxy, halogen). This composite structural approach allows the molecule to simultaneously achieve high receptor affinity, selectivity, and metabolic stability.
2Reliability
If high D3 receptor selectivity is achieved, then effectiveness in treating substance use disorders is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the ligand molecule into distinct functional segments: a substituted benzene ring portion, a central piperazine/piperidine ring, and terminal side chains. Each segment serves a specific function in receptor binding and selectivity. This segmented approach allows systematic optimization of each portion to achieve high D3 selectivity while maintaining reasonable structural complexity for drug development.
Data Source
AI summary
Disclosed herein novel dopamine D3 receptor selective antagonists/partial agonists compounds with high affinity and metabolic stability useful for the treatment of psychiatric and neurological disorders and as research and diagnostic tools. Also disclosed are methods of making the compounds.